Hepaticus, Inc. develops and commercializes products that accurately model human liver function in order to advance pharmaceutical development. We aim to advance pharmaceutical development for our partners with a proprietary human liver surrogate. Hepaticus produces small animal models containing functioning human liver cells. These animals serve as accurate models of human liver diseases such as hepatitis C, enabling the efficient development of treatments for devastating liver disorders. The same core technology produces robust models of human liver function, critical in the development process of all drugs in order to identify and modify compounds that may pose liver toxicity problems. Hepaticus participates in both the liver drug development and predictive toxicology markets. Competing models of human liver function are severely limited. Existing cell-based and animal models are high cost, immune-suppressed, too fragile to ship to customer sites, and do not consistently predict human disease or the potential failure of drugs due to liver toxicity. These limitations have slowed the pace of drug discovery and contributed to the fact that 40% of all drug failures are due to liver toxicity, undetected in the drug development process. Our products are designed to open this bottleneck. Accurately modeling human liver functionality and delivering this functionality reliably unlocks immediate business opportunities for Hepaticus and its partners. Hepaticus, Inc. is based on the research of Drs. George and Catherine Wu, professors at the University of Connecticut Health Center. Hepaticus holds an exclusive license to the worldwide issued patent covering the proprietary technology. Hepaticus, Inc. is privately held and was established in 2003. The company's facilities are located in Connecticut.
Cellestis Limited is an Australia-based company that is principally engaged in the developing, manufacturing and marketing of medical diagnostic products. The Company commercialises and develops QuantiFERON technology (QFT) worldwide. It operates in three principal areas: Australia (including Japan), the United States and Europe. The Company’s core business functions (marketing, research and development, manufacturing and finance) are located in Australia, with sales, marketing and distribution also operating in the United States and Europe (Germany). The Company’s wholly owned subsidiaries include Cellestis Inc, Cellestis International Pty Ltd, Cellestis (R&D) Pty Ltd, Cellestis GmbH and Cellestis Asia Kabushiki Kaisha. (Source: ARS)
http://www.platform-diagnostics.com
Formed in 2002, Platform Diagnostics is financed by venture capital investment. We are focused on delivering an affordable, digital rapid immunoassay in response to the demands of the POC market. The integration of a broad range of disciplines has allowed us to develop a new technology - Capillary Agglutination Technology (CAT). CAT provides a platform for digital, rapid, low cost diagnostic tests perfectly suited to the expanding POC market and overcomes the limitations of currently available techniques. Cost, intellectual property, end-user expectations and added distribution chain margins are all factors restricting entry into this market sector. Our founders bring expertise in clinical serology, microbiology, rapid immunoassay, magnetic particles, impedance, life sciences and gene reporter systems. Together with an impressive pedigree of invention, patent prosecution, problem solving and commercial focus, the company is set to revolutionise the POC diagnostic test market. More recently, BBI Holdings Plc and Carclo plc have undertaken to invest in Platform Diagnostics with a view to commercialising this innovative technology.
Genome Technologies, LLC. (GT) is a research-driven biotechnology/ genomics company. Our aim is the discovery of disease-causing genes and key genetic and molecular markers with a variety of applications. Genome Technologies has developed a powerful Functional Genomic Fingerprinting (FGF) technology that can be used to rapidly identify the defective genes that cause genetic diseases. This novel genomics technology can be applied to reveal the genetic basis of major illnesses such as hypertension, type II diabetes, allergies, asthma, and Alzhiemer's disease; and it can identify the offending genetic defects in less time and at a significantly reduced cost than could be achieved with other existing genomic research techniques. This platform technology can be used to enable pharmaceutical, agricultural and diagnostic companies to develop their future products rapidly and at a highly reduced cost. This unique technology is possible at Genome Technologies because our professionals have extensive experience and capabilities in bioinformatics and computational biology, and a deep understanding of genome biology, especially as it relates to human morphology and physiology.
Nysa Membrane Technologies has developed a novel, patent-pending membrane-based platform technology with broad worldwide applications in protein purification and other biological & industrial separations. Nysa's proprietary membranes represent a truly disruptive technology, with dramatic cost and performance advantages over conventional membrane and resin-based separation technologies. Nysa has exploited its revolutionary technology to develop high value products for specific large and growing markets such as large-scale bioprocessing, small-scale bioanalytics, food & beverage processing, and water treatment.
Founded in 1997, Industrial Science & Technology Network, Inc. ("ISTN") is a dynamic, innovative advanced technology company specializing in the development of nanotechnology-enabled products. These products rely on the control of material composition, form and structure at the sub-micron level to deliver a superior combination of cost-effectiveness and performance. The Company's proprietary technology platform, which is based on over 10 years of R&D in organic-inorganic nanostructures, can effectively address customer and end-user needs in a variety of large markets, including building products, chemicals, communications, defense, electronics, medical devices, pharmaceuticals and transportation. In order to enhance its positioning in today's increasingly competitive intellectual property environment, the Company is committed to delivering continued innovation through a fast-paced, highly responsive approach to product development. ISTN's objective is to utilize its platform technology to develop nanotechnology-enabled products for three highly promising application areas- industrial products, opto-electronics and biotechnology. The Company's primary commercialization strategy is to build mutually beneficial relationships with leading manufacturers in these industries to accelerate the path to market of its products. These strategic partnerships allow ISTN to leverage its partners' vast knowledge of market dynamics and commercialize its products without the substantial initial investment required to establish in-house manufacturing capabilities. Meanwhile, they enable the manufacturer to capitalize on the tremendous commercial potential of nanotechnology without having to invest significant internal resources. ISTN is also willing to license a mature technology to a corporate partner or work with investors and partners to create spin-off companies built around ISTN technology. An example of the arrangement mentioned above is ISTN's joint development partnership with Optimax Technology Corporation, a leading manufacturer of polarizers for the LCD industry, to create a next-generation anti-reflection coating for LCD's and explore other novel applications of optical nanotechnology. This relationship also highlights ISTN's commitment to continuous innovation. With the ever-increasing pace of technical advancement in the industry, ISTN believes that a dominant intellectual property portfolio is not enough to maintain a strong competitive position. Consequently, it works with its partners on new R&D initiatives even as it is still preparing to roll out its first co-developed product. Since its founding, ISTN has also teamed with a variety of other corporations in its target application areas, including Armstrong World Industries, Dow Chemical, PPG Industries and Taiwan Synthetic Rubber. In addition, the Company has received numerous research grants from government agencies such as Ben Franklin Technology Partners, the U.S. Department of Energy, the U.S. National Institutes of Health (NIH), and Taiwan's Industrial Technology and Research Institute (ITRI). Because of its R&D team's extensive experience in working with government laboratories and leading research universities, the Company is also able to selectively leverage the fundamental knowledge produced by these institutions. Laboratories and universities with which ISTN has collaborated include the National Institute of Standards and Technology (NIST), Pacific Northwest National Laboratory (PNNL), Sandia National Laboratories, Brown University, Cornell University, the University of Cincinnati, the University of Maryland, and the University of Michigan.
ReInnervate is developing new and innovative ways to manage the growth and function of cultured cells. Its technologies have multiple applications and will be particularly relevant to the control of stem cell differentiation. ReInnervate is a spin-out biotechnology company emanating from research conducted at Durham University. The Company was established in July 2002 to commerialise technology developed by its founding scientist working in the field of stem cell biology and developmental neuroscience. ReInnervate specialises in the development of enabling technologies to facilitate research into cell growth and function in vitro with immediate applications to research and development in the biotechnology and pharmaceutical sectors. Aspects of the Company's research are also suitable for development into diagnostic tools and have potential therapeutic applications. Currently, ReInnervate either directly or indirectly employs around 10 staff, including 6 PhD's with many years combined experience in cell biology and physical science. The Company operates from state-of-the-art laboratories within the University and has access to modern research facilities. The company has raised >£0.5M from various sources to support its initial research and development programmes and is seeking additional inward investment to bring its technologies to market.
Tetragenetics, Inc. is an early-stage biotechnology company meeting the needs of customers who seek a cost-effective alternative platform technology for the production of genetically engineered proteins. We accomplish this by harnessing the unique biology of Tetrahymena thermophila. Our technology is particularly well suited to the production of eucaryotic membrane and secretory proteins that are difficult to express in conventional systems. Such proteins include vaccine antigens, monoclonal antibodies, and a variety of therapeutic proteins for the treatment and prevention of human and animal disease. Development of recombinant subunit vaccines against human pathogens is now underway, and long-range efforts are being directed towards large-scale expression of genetically engineered monoclonal antibodies. Additionally, we are actively pursuing both an internal pipeline of hard-to-make proteins and monoclonal antibodies, as well as proteins in partnership with a number of biopharmaceutical companies.
Headquartered in Dallas, Texas, Hybrigen, Inc. is a privately-held biotechnology Company that has developed and commercialized proprietary proteomic platform technologies that dramatically accelerate the precise identification and characterization of high-value drug targets. Using these technologies, Hybrigen succeeds at discovering drug targets that are not found with other genomic and proteomic systems.
IatroQuest Corporation (www.iatroquest.com) is shaping the future of biosensing using a revolutionary patented technological platform called Bio-AlloyÔ, which combines biotechnology, advanced semi-conductor materials, nanotechnology and photonics. Bio-AlloyÔ makes a wide range of products possible in several market segments, such as biodefense, life sciences research and point-of-care diagnostics. Bio-AlloyÔ has unique characteristics that enable rapid detection and quantification, with a high degree of sensitivity and specificity without using markers, of a wide range of biological agents as well as small chemical molecules.
Medgenics, Inc. is a holding company with one wholly owned subsidiary Medgenics Medical Israel Ltd. (formerly Biogenics Ltd.). The Company and its subsidiary are engaged in the research and development of products in the field of biotechnology and associated medical equipment. The Company is considered as a development-stage company. The Company is developing an approach to treating chronic diseases, using a platform technology, a biological Biopump, enabling patients to produce their own natural human protein therapy. The Biopump technology is made from the patient’s own skin and is implanted in a procedure to work inside the patient’s body, to produce and deliver the active protein steadily over a sustained period to treat the targeted disease. The Company has completed the design, fabrication and evaluation of the key devices required for harvesting patient micro-organs and implanting Biopumps, including EPODURE, back into patients. (Source: ARS)
Farmacule BioIndustries Pty Limited (Farmacule) is an Australian biotechnology company focused on developing the country's first sustainable molecular farming industry. Our name has been derived from Farmacule's core business interest - the farming of molecules. The company was formed in 2001 to develop a molecular farming industry with the INPACT platform technology developed by the Queensland University of Technology (QUT) in Brisbane, Australia. Farmacule's shareholders include INPACT's inventors, QUT and private equity interests associated with Australian investment bank ORBIT CAPITAL.
Emerillon Therapeutics Inc. is a privately owned company specialized in infectious diseases. Emerillon has unique human genetics and mouse genetics platforms that have yielded novel therapeutic targets in many disease indications with large markets. Emerillon has prioritized a program in malaria for development focus, and continues limited research activity in pipeline development.
Phenomenome Discoveries Inc. is a privately owned company located in Saskatoon, Canada. Processing samples since December 2000, Phenomenome is the first company in the world to make non-targeted metabolomic investigation of complex biological samples commercially available using its proprietary DISCOVAmetricsÔ metabolite analysis and informatics platform. Phenomenome Informatics, a division of Phenomenome Discoveries Inc, in November 2004 launched Phenomenome ProfilerÔ, the first instrument-independent informatics platform designed for the visualization and interpretation of mass spectrometry small molecule data. Phenomenome has in-house and collaborative research programs in human health, pharmacometabolomics, and agriculture. www.phenomenome.com
Pharmexa is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer and chronic diseases, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Pharmexa's leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Genimmune (subsidiary of Innogenetics), IDM Pharma and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.
http://www.noabbiodiscoveries.com
NoAb BioDiscoveries provides a wide range of innovative drug discovery services and tools designed to accelerate the drug development process. Our focus is on lead selection and optimization. We provide pharmaceutical developers In Vivo PK (Pharmacokinetics) studies, In Vitro ADME (Absorption, Distribution, Metabolism, and Excretion) assays, Bioanalytical services, and Gene Expression profiling of drug effects. Our state-of-the-art 12,600 sq. ft. research facility is located in the heart of one of North America's key biotech hubs, with convenient access from centers around the world. Our team of experienced scientists can assist in designing the best strategy and protocols to suit any drug discovery need.
Stem Cell Therapeutics Corp. (SCT) is a Canada-based biotechnology company-focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is engaged in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair neurological functions lost due to disease or injury. SCT’s product, NTx-265, targets the treatment of stroke by repurposing approved and clinically well defined drugs. NTx-265 is a therapeutic regimen of two drugs being developed by SCT for the treatment of stroke. The Company is in the process of commencing a Phase IIb prospective, randomized, double-blind, placebo controlled study of NTx- 265 termed REGENESIS. (Source: ARS)
EvoGenix Ltd is a rapidly developing biotechnology company established in August, 2001. The company was originally founded with venture capital backing to develop key discoveries in the field of protein engineering made by scientists from Australia's Co-operative Research Centre for Diagnostics and CSIRO Division of Health Sciences and Nutrition. Further investment completed in 2004 brought about an expansion of the company with new board members and executives appointed. In addition, in 2004, EvoGenix entered an important strategic alliance with a recently established Californian antibody engineering company, Absalus Inc. This alliance brought about significant growth in the capabilities of the two companies in the antibody sector, with a newly integrated technology platform for delivering potent humanised therapeutic products ready for clinical development. This alliance was formalised through the merger of the two companies in April 2005. EvoGenix now has established laboratory and business development operations in Melbourne, Australia, a head office in Sydney and a key operation in Mountain View, California, USA, with responsibility for evaluating and securing new opportunities for the company in both technology and products. Following completion of the integration of the operations of Absalus Inc, now named EvoGenix Inc, the company listed on the Australian Stock Exchange in August 2005, under the code EGX. In December, 2006, EvoGenix raised a further A$5 million from existing investors. In May 2007, the company received a proposal to merge with Peptech Ltd and this was approved by EvoGenix shareholders on August 9, 2007.
CombiMatrix Corporation, formerly Acacia Research-CombiMatrix, is a biotechnology company, with a subsidiary, CombiMatrix Molecular Diagnostics, Inc. (CMDX). CombiMatrix's electrochemical manufacturing process utilizes standard semiconductor technology, software and chemistry to build arrays of materials. The Company's CustomArray products are deoxyribonucleic acid (DNA) microarrays, which have uses in pharmaceutical, biotech and agrochemical industries, as well as in research and government markets. The Company also uses its technology in synergistic internal programs for diagnostics development, drug development, and biodefense in addition to partnerships for nanomaterials development.
Genomics One, a world leader in genomics and post-genomics technologies, is a fully integrated biotechnology company committed to the creation of shareholder value through innovation in the fields of genomics, proteomics and monoclonal antibody development. The mission of Genomics One is to generate profitable applications in research, therapeutics, diagnostics and pharmaceuticals.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory